Search

Your search keyword '"Shon, K"' showing total 190 results

Search Constraints

Start Over You searched for: Author "Shon, K" Remove constraint Author: "Shon, K"
190 results on '"Shon, K"'

Search Results

5. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

6. Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies

8. Intra-arterial Liver Isolation Chemotherapy via an Implantable Vascular Access Device to Facilitate Repeated Vascular Access for Patients with Hepatic Metastases from Colorectal Cancer (The SYS-CAPLIOX Trial)

10. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

13. Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies

14. The ALERT model of care for the assessment and personalized management of patients with lymphoedema.

18. CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity

19. Discovery of a Covalent Inhibitor of KRASG12C(AMG 510) for the Treatment of Solid Tumors

20. Discovery of (R)‑8-(6-Methyl-4-oxo-1,4,5,6-tetrahydro-pyrrolo[3,4‑b]-pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)-amino)-quinazolin-4(3H)‑one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological...

21. Phase equilibrium in a special class of polydisperse fluid models.

22. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors

24. Correction to Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511

25. Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511

26. Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases

27. Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability

28. Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives

29. Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors

30. Correction to Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511

31. CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity

32. Design, Synthesis, and Biological Evaluation of Potent c-Met Inhibitors

44. Structural requirements of the epidermal growth factor receptor for tyrosine phosphorylation of eps8 and eps15, substrates lacking Src SH2 homology domains

Catalog

Books, media, physical & digital resources